Repolarization properties: Novel evidence from dynamic QT analysis

Annals of Noninvasive Electrocardiology

Volumn 9, Issue 3, 2004, Pages 228-233

  Kaya, Dayimi ^a   Guler, Cem ^a   Esen, Ali Metin ^a   Barutcu, Irfan ^a,b   Dincel, Cetin ^a  

^a AFYON KOCATEPE UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Erectile dysfunction; QT dynamicity; Sildenafil; Ventricular arrhythmia

Indexed keywords

SILDENAFIL; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE;

ADULT; ARTICLE; BODY POSITION; CLINICAL FEATURE; CONTROLLED STUDY; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE CONTRACTION; HOLTER MONITORING; HUMAN; MALE; PRIORITY JOURNAL; QT INTERVAL; REST; RR INTERVAL; AGED; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART MUSCLE CONDUCTION SYSTEM; IMPOTENCE; MIDDLE AGED; NONPARAMETRIC TEST; ORAL DRUG ADMINISTRATION; RISK FACTOR;

ADMINISTRATION, ORAL; AGED; ELECTROCARDIOGRAPHY, AMBULATORY; HEART CONDUCTION SYSTEM; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 3843090651     PISSN: 1082720X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1542-474X.2004.93554.x     Document Type: Article

References (30)

1. Boolell M, Gepi-Attee S, Gingell JC, et al. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996;78:257-261.
2. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998;338:1397-1404.
3. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
4. Feenstra J, van Drie-Pierik RJ, Lacle CF, et al. Acute myocardial infarction associated with sildenafil. Lancet 1998;352:957-958.
5. Hayashi K, Minezaki KK, Narukawa M, et al. Atrial fibrillation and continuous hypotension induced by sildenafil in an intermittent WPW syndrome patient. Jpn Heart J 1999;40:827-830.
6. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation 1999;99:168-177.
7. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999;33:273-282.
8. Phillips BG, Kato M, Pesek CA, et al. Sympathetic activation by sildenafil. Circulation 2000;102:3068-3073.
9. Piccirillo G, Nocco M, Lionetti M, et al. Effects of sildenafil citrate (Viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure. Am Heart J 2002;143:703-710.
10. Geelen P, Drolet B, Rail J, et al. Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation 2000;102:275-277.
11. Chiang CE, Luk HN, Wang TM, et al. Effects of sildenafil on cardiac repolarization. Cardiovasc Res 2002;55:290-299.
12. Coumel P, Maison-Blanche P, Badilini F. Dispersion of ventricular repolarization: Reality? Illusion? Significance? Circulation 1998;97:2491-2493.
13. Hintze U, Vach W, Burchardt H, et al. DIAMOND Study Group: QT interval dynamics predict mortality in high-risk patients after myocardial infarction. Scand Cardiovasc J 2002;36:276-281.
14. Extramiana F, Neyroud N, Huikuri HV, et al. QT interval and arrhythmic risk assessment after myocardial infarction. Am J Cardiol 1999;83:266-269.
15. Neyroud N, Maison-Blanche P, Denjoy I, et al. Diagnostic performance of QT interval variables from 24-h electrocardiography in the long QT syndrome. Eur Heart J 1998;19:158-165.
16. Lande G, Maison-Blanche P, Fayn J, et al. Dynamic analysis of dofetilide-induced changes in ventricular repolarization. Clin Pharmacol Ther 1998;64:312-321.
17. Lang CC, Flapan AD, Neilson JM. The impact of QT lag compensation on dynamic assessment of ventricular repolarization: Reproducibility and the impact of lead selection. Pacing Clin Electrophysiol 2001;24:366-373.
18. Milligan PA, Marshall SF, Karlsson MO. A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. Br J Clin Pharmacol 2002;53(Suppl. 1):45S-52S.
19. Franz MR, Swerdlow CD, Liem LB, et al. Cycle length dependence of human action potential duration in vivo. Effects of single extrastimuli, sudden sustained rate acceleration and deceleration, and different steady-state frequencies. J Clin Invest 1988;82:972-979.
20. Lee SD, Dorian P, Geist M, et al. Validation of a non-invasive measure of local myocardial repolarization in a conscious human model: Adaptation of repolarization to changes in rate. J Cardiovasc Electrophysiol 1999;10:1171-1179.
21. Berger RD, Kasper EK, Baughman KL, et al. Beat-to-beat QT interval variability: Novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy. Circulation 1997;96:1557-1565.
22. Jackson G, Benjamin N, Jackson N, et al. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999;83;13C-20C.
23. Arruda-Olson AM, Mahoney DW, Nehra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: A randomized crossover trial. JAMA 2002;287:719-925.
24. Agelink MW, Ullrich H, Brockmeyer NH. Sildenafil does not influence autonomic neurocardiac control assessed by standard measurements of heart rate variability. Circulation 2001;104:E145.
25. Alpaslan M, Onrat E, Samli M, et al. Sildenafil citrate does not affect QT intervals and QT dispersion: An important observation for drug safety. Ann Noninvasive Electrocardiol 2003;8:14-17.
26. Heart rate variability: Standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996;93:1043-1065.
27. Sadovsky R, Miller T, Moskowitz M, et al. Three-year update of sildenafil citrate (Viagra) efficacy and safety. Int J Clin Pract 2001;55:115-128.
28. DeBusk R, Drory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: Recommendations of The Princeton Consensus Panel. Am J Cardiol 2000;86:175-181.
29. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: Absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002;53(Suppl. 1):5S-12S.
30. Muirhead GJ, Faulkner S, Harness JA, et al. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. Br J Clin Pharmacol 2002;53(Suppl. 1):37S-43S.